CA2668347C - Tissue plasminogen activator variant uses - Google Patents

Tissue plasminogen activator variant uses Download PDF

Info

Publication number
CA2668347C
CA2668347C CA2668347A CA2668347A CA2668347C CA 2668347 C CA2668347 C CA 2668347C CA 2668347 A CA2668347 A CA 2668347A CA 2668347 A CA2668347 A CA 2668347A CA 2668347 C CA2668347 C CA 2668347C
Authority
CA
Canada
Prior art keywords
tenecteplase
catheter
bfr
visit
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2668347A
Other languages
English (en)
French (fr)
Other versions
CA2668347A1 (en
Inventor
Martha E. Blaney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA2668347A1 publication Critical patent/CA2668347A1/en
Application granted granted Critical
Publication of CA2668347C publication Critical patent/CA2668347C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/285—Catheters therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M2025/0019—Cleaning catheters or the like, e.g. for reuse of the device, for avoiding replacement

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2668347A 2006-11-07 2007-10-30 Tissue plasminogen activator variant uses Active CA2668347C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86475806P 2006-11-07 2006-11-07
US60/864,758 2006-11-07
US98348907P 2007-10-29 2007-10-29
US60/983,489 2007-10-29
PCT/US2007/082933 WO2008070353A2 (en) 2006-11-07 2007-10-30 Tissue plasminogen activator variant uses

Publications (2)

Publication Number Publication Date
CA2668347A1 CA2668347A1 (en) 2008-06-12
CA2668347C true CA2668347C (en) 2017-06-20

Family

ID=39362326

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2668347A Active CA2668347C (en) 2006-11-07 2007-10-30 Tissue plasminogen activator variant uses

Country Status (10)

Country Link
US (1) US8916148B2 (https=)
EP (1) EP2086571A2 (https=)
JP (1) JP5871449B2 (https=)
AR (1) AR063603A1 (https=)
CA (1) CA2668347C (https=)
CL (1) CL2007003211A1 (https=)
PE (2) PE20081488A1 (https=)
TW (1) TW200826981A (https=)
UY (1) UY30693A1 (https=)
WO (1) WO2008070353A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ533029A (en) 2001-11-26 2006-05-26 Genentech Inc Composition useful for removal of fibrin-bound blood clot from a catheter comprises water, a plasminogen activator and an alcohol
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
CA2668347C (en) 2006-11-07 2017-06-20 Genentech, Inc. Tissue plasminogen activator variant uses
JP6375112B2 (ja) 2010-12-23 2018-08-15 ジェノヴァ バイオファーマシューティカルズ リミテッド テネクテプラーゼの医薬組成物
GB201415062D0 (en) * 2014-08-26 2014-10-08 Aplagon Oy Therapeutic
PL3209767T3 (pl) * 2014-10-21 2021-01-11 Gennova Biopharmaceuticals Ltd. Nowy sposób oczyszczania do izolacji i komercyjnej produkcji zrekombinowanego tnk-tpa (tenekteplazy)

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI831484A7 (fi) 1982-05-05 1983-11-06 Genentech Inc Ihmiskudoksen plasminogeenien aktivaattori.
US5000185A (en) 1986-02-28 1991-03-19 Cardiovascular Imaging Systems, Inc. Method for intravascular two-dimensional ultrasonography and recanalization
US5019096A (en) 1988-02-11 1991-05-28 Trustees Of Columbia University In The City Of New York Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
US5270198A (en) 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
GB8820945D0 (en) 1988-09-07 1988-10-05 Smith & Nephew Medical articles
NZ230808A (en) 1988-10-24 1993-04-28 Squibb & Sons Inc Pharmaceutical compositions and combinations containing an angiotensin-converting enzyme inhibitor and a thrombolytic agent
WO1991017724A1 (en) 1990-05-17 1991-11-28 Harbor Medical Devices, Inc. Medical device polymer
US5399158A (en) 1990-05-31 1995-03-21 The United States Of America As Represented By The Secretary Of The Army Method of lysing thrombi
US5363754A (en) 1991-09-03 1994-11-15 Grainco Queensland Co-Operative Association Limited Apparatus for preparing animal feedstuff from cotton seed
ATE155816T1 (de) 1992-06-03 1997-08-15 Genentech Inc Varianten des gewebeplasminogenaktivators mit verbesserter therapeutischer wirkung
US5688516A (en) 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US5362754A (en) 1992-11-12 1994-11-08 Univ. Of Tx Md Anderson Cancer Center M-EDTA pharmaceutical preparations and uses thereof
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DK0730590T3 (da) 1993-11-24 2001-03-19 Du Pont Pharm Co Isoxazolin og isozazol fibrinogenreceptorantagonister
US5885967A (en) 1994-03-04 1999-03-23 Eli Lilly And Company Antithrombotic agents
US5509896A (en) 1994-09-09 1996-04-23 Coraje, Inc. Enhancement of thrombolysis with external ultrasound
US5556380A (en) 1995-04-05 1996-09-17 Duke University Method for removing fibrin sheaths from catheters
US5772640A (en) 1996-01-05 1998-06-30 The Trustees Of Columbia University Of The City Of New York Triclosan-containing medical devices
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
US5932299A (en) 1996-04-23 1999-08-03 Katoot; Mohammad W. Method for modifying the surface of an object
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5837688A (en) 1996-11-27 1998-11-17 Gelfand; Mathew I. Use of thrombolytic reagents for prevention of vascular disease
AU5526098A (en) 1996-12-23 1998-07-17 Biochem Pharma Inc. Bicyclic thrombin inhibitors
GB9626795D0 (en) 1996-12-23 1997-02-12 Geistlich Soehne Ag Combating infection in delivery systems
US5981826A (en) 1997-05-05 1999-11-09 Georgia Tech Research Corporation Poly(vinyl alcohol) cryogel
JPH10328293A (ja) 1997-06-04 1998-12-15 Unitika Ltd 医療用具及びその製造方法
US6206914B1 (en) 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
US6166007A (en) 1998-07-02 2000-12-26 Sodemann; Klaus Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof
US6174537B1 (en) 1998-09-25 2001-01-16 Becton, Dickinson And Company Catheter flush solution and method for its use
EP1189663A2 (en) 1999-03-11 2002-03-27 Du Pont Pharmaceuticals Company Synergy between low molecular weight heparin and platelet aggregation inhibitors, for preventing and treating thromboembolic disorders
CN1346292A (zh) 1999-03-11 2002-04-24 杜邦药品公司 凝血因子Xa抑制剂与阿司匹林、组织纤溶酶原激活物(TPA)、GPⅡb/Ⅲa拮抗剂、低分子量肝素或肝素联合用于治疗血栓形成
CA2302720C (en) 1999-03-29 2009-07-14 Ed Geistlich Sohne Ag Fur Chemische Industrie Anticoagulant/sterilizing compositions and methods
US6187768B1 (en) 1999-06-01 2001-02-13 Becton, Dickinson And Company Kit for flushing medical devices and method of preparation
EP1060747A3 (en) 1999-06-16 2001-12-05 New York Blood Center, Inc. Fibrin(ogen) degradation and clot lysis by fibrinolytic metalloproteinase
US6592564B2 (en) 1999-07-23 2003-07-15 Vasca, Inc. Methods and kits for locking and disinfecting implanted catheters
US6350251B1 (en) * 2000-01-18 2002-02-26 Biolink Corporation Biocidal locks
US20010031981A1 (en) 2000-03-31 2001-10-18 Evans Michael A. Method and device for locating guidewire and treating chronic total occlusions
EP1284780B1 (en) 2000-05-10 2008-05-07 Ash Access Technology, Inc. A catheter lock solution including a photo-oxidant
AU2001285245A1 (en) 2000-08-25 2002-03-13 Organ Recovery Systems, Inc. Methods of thrombolytic organ treatment and repair
US20050215978A1 (en) * 2001-05-25 2005-09-29 Ash Stephen R Method of enhancing catheter patency using a citrate salt catheter lock solution
NZ533029A (en) * 2001-11-26 2006-05-26 Genentech Inc Composition useful for removal of fibrin-bound blood clot from a catheter comprises water, a plasminogen activator and an alcohol
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
ATE354380T1 (de) 2003-02-03 2007-03-15 Polaschegg Hans-Dietrich Dr Te Zusammensetzung zur prävention von infektionen durch subkutane prothesen
US7696182B2 (en) * 2004-11-02 2010-04-13 Nd Partners, Llc Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
US7749529B2 (en) 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
CA2668347C (en) 2006-11-07 2017-06-20 Genentech, Inc. Tissue plasminogen activator variant uses

Also Published As

Publication number Publication date
WO2008070353A2 (en) 2008-06-12
AR063603A1 (es) 2009-02-04
EP2086571A2 (en) 2009-08-12
TW200826981A (en) 2008-07-01
CL2007003211A1 (es) 2008-05-30
PE20081488A1 (es) 2008-10-30
JP5871449B2 (ja) 2016-03-01
US8916148B2 (en) 2014-12-23
JP2010509229A (ja) 2010-03-25
WO2008070353A3 (en) 2008-08-28
US20120270299A1 (en) 2012-10-25
UY30693A1 (es) 2008-05-02
PE20120639A1 (es) 2012-05-26
CA2668347A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
Jilani et al. Tissue plasminogen activator
Grunwald et al. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis
Patel et al. Quality improvement guidelines for percutaneous management of acute lower-extremity ischemia
Bagnall et al. Continuous infusion of low-dose urokinase in the treatment of central venous catheter thrombosis in infants and children
Hyers et al. Antithrombotic therapy for venous thromboembolic disease
CA2668347C (en) Tissue plasminogen activator variant uses
Blaney et al. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study)
Jacobs et al. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children
Davis et al. Activity and dosage of alteplase dilution for clearing occlusions of venous-access devices
US20100330083A1 (en) Plasminogen activator variant formulations
Tumlin et al. A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 3
Doelare et al. Major bleeding during thrombolytic therapy for acute lower limb ischaemia: value of laboratory tests for clinical decision making, 17 years of experience
Deitcher et al. Alfimeprase: a novel recombinant direct-acting fibrinolytic
Mayo Catheter-related thrombosis
Patel et al. Tissue Plasminogen Activator Therapy
US20060078555A1 (en) Intraventricular hemorrhage thrombolysis
Tebbi et al. A phase III, open-label, single-arm study of tenecteplase for restoration of function in dysfunctional central venous catheters
US20110229454A1 (en) Use of Prourokinase and Variants Thereof in Facilitated Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction
Yildiz et al. Outpatient use of tPA to recanalize thrombosed native fistulas a case series and discussion of literature
Swischuk et al. Differentiating pharmacologic agents used in catheter-directed thrombolysis
Soylu et al. Efficacy of local instillation of recombinant tissue plasminogen activator for restoring occluded central venous catheters in neonates
Fishbane et al. Improvement of hemodialysis catheter function with tenecteplase: a phase III, open-label study: TROPICS 4
Chaplin The use of tranexamic acid in reducing bleeding complications
Goubran et al. Coagulation and Anticoagulants
MXPA03005641A (es) Uso de factor vii activado de coagulacion para tratar sangrados graves inducidos por terapia trombolitica.

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250430